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Lynch syndrome is the most common form of hereditary colorectal cancer. It is caused by
genetic mutations in the DNA mismatch repair (MMR) pathway. The MMR pathway is a cellular
mechanism for repairing nucleotide mismatches that arise during DNA replication. Generally,
MSH2-MSH6 heterodimers bind mismatches then are themselves bound by a second mismatch
repair heterodimer, MLH1-PMS2. This complex regulates an exonuclease, Exo1, to remove the
mismatch-containing DNA that is re-synthesized and sealed by DNA polymerase δ and DNA
ligase. There are multiple models to explain the specific MMR molecular mechanism including
the molecular switch model. In this model, mismatch binding acts as an exchange factor that
reduces ADP affinity and increases ATP affinity in MSH2-MSH6. In the molecular switch
model, the form of MSH2-MSH6 that is not bound to DNA and ATP is incapable of initiating
downstream repair, thus MMR is “off”. The DNA and ATP-bound form of MSH2-MSH6 is
capable of initiating repair, thus MMR is “on”. The MMR pathway also acts as a sensor for some
kinds of DNA damage and can activate a cell cycle arrest and apoptosis response. The DNA
methylating agent, N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), causes O6-methylguanine
(O6-me-G) lesions that strongly activate the MMR-dependent DNA damage response by causing
O6-me-G:T mismatches. Most work on the MMR pathway has been in vitro biochemistry in

lower organisms. Because of this, there is a substantial knowledge gap about the molecular
mechanism of MMR in vivo in humans. Understanding the cellular MMR mechanism in repair
and the damage response will have the greatest impact clinically for Lynch syndrome patients.
Using three MSH2 mutants in the ATPase domain of the protein that we hypothesized would
impair the molecular switch model of MMR at different steps, we restored expression of MSH2
in an MSH2-null cell line. Using in vivo chromatin localization, MMR and cell cycle arrest
assays, we generated data that support the molecular switch model of MMR in vivo in humans
for both repair and activation of the MMR-dependent DNA damage response to MNNG lesions.
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Chapter I:
Introduction
A. Colorectal Cancer
Colorectal cancer (CRC) is the third most commonly-diagnosed cancer for both men and
women in the United States and is the third-leading cause of cancer deaths (American Cancer
Society, 2013). Because of its severity, CRC has been a focus of cancer research for years;
however, owing to its location, CRC has also presented researchers with a unique opportunity to
study the progressive development of solid tumors. Early cancer genetics work resulted in the
hypothesis that tumorigenesis required the acquisition of sequential mutations that gave the cells
in which they occurred a growth advantage over normal, neighboring cells (Fearon and
Vogelstein, 1990). Each ensuing sporadic mutation in those already mutated cells enhanced the
growth advantage and progressed the cells from benign early-stage adenoma through to
malignant colorectal carcinoma (Fearon and Vogelstein, 1990). Since the median age of CRC
diagnosis for the population at large is 68-72 (American Cancer Society, 2011), this multi-step
model of CRC tumorigenesis required the gradual acquisition of sporadic mutations taking place
over decades. This genetic model can serve as a framework for interpreting sporadic CRC
incidences in the general population, but how to explain incidences of CRC with a much earlier
age of onset, presumably before so many mutations could accumulate over the decades, as well
as cases of the disease that seem to run in families (Kinzler and Vogelstein, 1996)? Using the
CRC and retinoblastoma genetic framework developed by Fearon and Vogelstein and Knudson
(Knudson, 1971), these hereditary forms of CRC could be explained by one key inherited
mutation that fast-tracked an individual towards CRC. There are two main forms of hereditary
CRC: Familial adenomatous polyposis (FAP) and Lynch syndrome (LS).
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a. Familial adenomatous polyposis
FAP is a form of hereditary CRC characterized by the development of hundreds to
thousands of adenomatous polyps starting in the second decade of life. Although a rare form of
CRC, it affects approximately 1:10,000 people (Church, 2009), the sheer number of adenomas
that develop in FAP patients virtually guarantees that some will progress into CRC. Typically the
only recourse is to remove the colon.
FAP is an autosomal dominant form of hereditary CRC. Studies of familial genetics
demonstrated a linkage between FAP and a marker on chromosome 5q21 (Bodmer et al., 1987)
even though the disease was first described in the mid-19th century. The underlying cause was a
mutation in the APC gene, which produces the adenomatous polyposis coli (APC) protein
(Olschwang et al., 1991). APC is a scaffolding protein involved in the Wnt signaling pathway
and sequesters β-catenin, a transcription factor also involved in cell adhesion. FAP-associated
mutations typically result in truncations of APC that result in a reduced ability to bind and
sequester β-catenin thereby causing increased proliferation in colon cells. Inheriting a single
mutation in the APC gene is sufficient to diagnose FAP individuals even though tumorigenesis
requires the loss of the second APC allele.
b. Lynch syndrome
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, is
differentiated from FAP by its lack of multiple adenomatous polyps in the colon and greatly
increased risk of developing extra-colonic tumors in addition to CRC, most notably endometrial,
stomach, ovarian, small intestine and pancreas (Watson and Lynch, 1993; Lynch et al., 2009).
Emerging evidence suggests that LS increases the risk for breast, bladder and prostate cancers as
well (Engel et al., 2012). LS is much more common than FAP and affects approximately 3% of
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total CRC cases (Lynch et al., 2009). Like FAP, familial genetics played a role in helping to
define this form of hereditary CRC. In 1966, a pathologist, Henry Lynch, published his findings
regarding two large families with high frequencies of specific carcinomas including many cases
of CRC (Lynch et al., 1966), which was supported by further studies of familial CRC (Boland
and Troncale, 1984).
Since LS lacks a highly noticeable phenotype like FAP, its defining characteristics are
important in order to distinguish LS from cases of sporadic CRC. International efforts to
characterize LS and aid in the identification of patients led to the development of the Amsterdam
II criteria in 1999 (Vasen et al., 1999) and revised Bethesda Guidelines in 2002 (Umar et al.,
2004). The defining characteristics of LS are summarized in Table 1-1. One of the primary LS
characteristics is microsatellite instability (MSI).
Microsatellites are short, repetitive sequences of DNA. The Bethesda Guidelines
recommends examining a panel of five known microsatellite regions for expansion or contraction
as almost all LS-associated cases of CRC exhibit significant MSI (Umar et al., 2004). Based on
the observation that LS tumors displayed significant MSI (Peltomäki et al., 1993a; Aaltonen et
al., 1993; Aaltonen et al., 1994) and given the role of prokaryotic MMR in fixing MSI,
researchers hypothesized that prokaryotic MMR homologues in humans might cause LS.
Additionally, eukaryotic MutS (Msh) and MutL (Mlh) homologues for bacterial MMR proteins
had been described in yeast (Reenan and Kolodner, 1992; Kramer et al., 1989) and mutations
within yeast Msh and Mlh caused MSI similar to that seen in human LS patients (Strand et al.,
1993). Studies initially associated LS with a locus on chromosome 2p (Peltomäki et al., 1993b)
before the discovery of human MutS homologue 2 (MSH2) and its association with LS causation
in 1993 (Leach et al., 1993; Fishel et al., 1993). Subsequent work discovered additional human
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Table 1-1. Diagnostic criteria for Lynch syndrome. Adapted from Vasen et al., 2007.
At least three relatives, including one first-degree relative, diagnosed with a LS-associated cancer
CRC diagnosis prior to the age of 50
LS-associated cancer diagnoses in at least two successive generations
Presence of synchronous or metachronous LS-associated tumors
Diagnosis of a family member’s LS-associated cancer prior to the age of 50
CRC with high MSI in a patient prior to the age of 60
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MutL homologues, MLH1 and PMS2 (Lindblom et al., 1993; Nicolaides et al., 1994;
Papadopoulos et al., 1994; Bronner et al., 1994), and MutS homologues, MSH6 (Palombo et al.,
1995; Drummond et al., 1995; Miyaki et al., 1997), involved in mismatch-binding and mismatch
repair and mutations that were also implicated in causing LS. Mutations in MLH1, MSH2 and
MSH6 account for approximately 95% of all LS-associated mutations (Peltomäki, 2005).
B. DNA Mismatch Repair
a. Prokaryotic MMR
The MMR pathway is a highly-conserved mechanism for repairing single nucleotide
mispairs and small insertion/deletion loops that can arise during replication. The components of
prokaryotic MMR have been well-characterized, most notably in the bacterium Escherichia coli,
where it was observed that mutations at certain loci in the E. coli genome, now known to
correspond to MMR genes, led to significantly higher genomic mutational frequencies (Cox,
1976).
In bacteria, mismatches are recognized by homodimers of MutS proteins with ADP
bound by one of the monomers (Su and Modrich, 1986; Lamers et al., 2000; Obmolova et al.,
2000). Binding to mismatches drives a MutS conformational change that simultaneously reduces
affinity for the mismatch and ADP and increases MutS affinity for ATP binding (Selmane et al.,
2003; Junop et al., 2001). This converts the MutS homodimer into a very stable, DNA-bound
clamp that diffuses from the mismatch freeing it to be recognized by another MutS homodimer
(Acharya et al., 2003). Iterative loading of ATP-bound, MutS clamps follows (Acharya et al.,
2003). These ATP-bound MutS clamps bind a second homodimer, MutL (Grilley et al., 1989),
which activates an endonuclease, MutH, in an ATP-dependent manner through direct interaction
(Welsh et al., 1987; Hall and Matson, 1999). MutH has specificity for unmethylated d(GATC)
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sequences (Welsh et al., 1987). Because newly replicated E. coli DNA is transiently
unmethylated, the methylation status of the d(GATC) sequence serves as the signal to ensure
repair strand specificity and direct MMR to the newly-synthesized DNA strand (Au et al., 1992).
Following incision of the repair strand by MutH, the DNA is unwound by DNA helicase II
(Yamaguchi et al., 1998) and excised by different exonucleases depending on the 5’ or 3’
orientation of the incision. Excision continues through the mismatch at which point DNA
Polymerase III resynthesizes an error-free DNA strand and it is ligated (Lahue et al., 1989;
Grilley et al., 1993).
b. Eukaryotic MMR
Because of genetic conservation, the eukaryotic MMR system is similar fundamentally to
the classical MMR system worked out in bacteria, but is more complex and has several notable
distinctions although the exact molecular mechanism linking mismatch binding to excision is
still unclear. Mismatch recognition is accomplished with MSH2-MSH6 heterodimers (Palombo
et al., 1995; Acharya et al., 1996), not MutS homodimers as in bacteria. Only the MSH6 subunit
directly binds mismatches through a conserved Phe-X-Glu motif like that found in bacterial
MutS, a motif that MSH2 lacks (Drotschmann et al., 2001). The result in both eukaryotic and
bacterial MMR is asymmetrical binding by the dimer subunits at mismatches. Iterative loading of
ATP-bound MSH2-MSH6 clamps on mismatch-containing DNA is similar between prokaryotes
and eukaryotes (Gradia et al., 1997; Gradia et al., 1999; Gradia et al., 2000), but downstream
licensing of MMR in humans requires binding MutL homologue heterodimers of MLH1-PMS2
in humans or Mlh1-Pms1 in yeast as opposed to MutL homodimers in bacteria (Zhang et al.,
2005; Mendillo et al., 2005). Additionally, there is no MutH homologue in human MMR;
however one of the MutL homologues, PMS2, possesses endonuclease activity as does Pms1 in
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yeast (Kadyrov et al., 2007; Kadyrov et al., 2006). In bacteria, MutS, MutL, mismatchcontaining DNA and ATP are sufficient to activate the endonuclease activity of MutH (Hall and
Matson, 1999), but additional factors are required in human MMR in order to activate PMS2
endonuclease activity and ensure the newly-replicated DNA strand is incised. The eukaryotic
DNA polymerase processivity factor, proliferating cell nuclear antigen (PCNA), and its clamp
loader, replication factor C (RFC), are required to both activate PSM2 endonuclease activity as
well as orient the DNA incision to the nascent strand (Pluciennik et al., 2010). The
homotrimeric, clamp-like PCNA accomplishes this because of its asymmetric faces. Loading of
PCNA at the 3’ ends of DNA via RFC, and PCNA’s subsequent diffusion along the DNA in the
same orientation, ensures that the incision made by PMS2 is restricted to new strands of DNA.
Ensuring MMR is restricted to a newly-replicated DNA strand and not the template strand is
vital to prevent the permanent introduction of mutations into the human genome. In humans,
MMR strand discrimination does not depend on transient hemimethylation at d(GATC)
sequences on the newly-synthesized DNA strand (Drummond and Bellacosa, 2001). Instead,
biochemical data suggests that human MMR restricts itself to nascent DNA strands through the
recognition of strand discontinuities such as those found between Okazaki fragments on the
lagging strand during DNA replication (Dzantiev et al., 2004; Constantin et al., 2005; Pluciennik
et al., 2010). Recent evidence also implicates the misincorporation of ribonucleotides into DNA
during replication as an additional source of strand discontinuities, and entry sites for MMR, as
they are being removed (Ghodgaonkar et al., 2013). Whereas the bacterial MMR system utilizes
different exonucleases depending on whether the MutH incision is upstream or downstream of
the mismatch, the human MMR system requires only one exonuclease, EXO1, which has 5’-to3’ exonuclease activity. However, the endonuclease activity of PCNA-activated PMS2 can incise
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nascent DNA upstream of a mismatch in order to direct EXO1 to the proper strand. Resynthesis
and ligation of the repaired DNA strand are done by the replication DNA polymerase δ and DNA
ligase.
C. MSH2-MSH6 protein domains
Central to the molecular mechanism of eukaryotic MMR is the conformational change in
the mismatch recognition heterodimer that accompanies mismatch binding. This conformational
change alters the nucleotide-binding states of the MSH2-MSH6 subunits and licenses the
downstream MMR process. MSH2 and MSH6, like MutS, are members of the ATP-binding
cassette (ABC) ATPase family (Hollenstein et al., 2007). Members of this family are involved in
diverse biological functions, but all contain ATP-binding and ATPase activity when dimerized.
The crystal structures of different prokaryotic MutS proteins have been solved (Obmolova et al.,
2000; Lamers et al., 2000) as has the MSH2-MSH6 heterodimer bound to mismatched DNA
(Warren et al., 2007).
Both MSH2 and MSH6 contain five domains: mismatch-binding, clamps, connector,
levers and ATPase (Figure 1-1). The mismatch-binding domain must allosterically communicate
a change in state to the ATPase domain through the intervening connector, clamp and lever
domains over approximately 100 angstroms (Warren et al., 2007). MSH2 and MSH6 have
composite ATPase domains at the carboxy-terminal dimerization interface. Each subunit’s
ATPase domain contains Walker A/B motifs for ATP-binding and hydrolysis in the presence of
magnesium cofactors (Warren et al., 2007). The ATPase domain of MSH2 is slightly more
ordered than that of MSH6 (Warren et al., 2007) and has an increased affinity for ADP (Mazur et
al., 2006, Heinen et al., 2011). In vitro biochemistry suggests that the human mismatch
recognition heterodimer binds mismatches in a (ADP)MSH2-MSH6(empty) state; mismatch
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Figure 1-1. MSH2-MSH6 crystal structure. Complete crystal structure of the MSH2-MSH6
heterodimer bound to ADP and G/T mismatched DNA (protein data bank ID 2O8B).
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binding reduces the affinity of MSH2 for ADP while increasing the MSH6 ATPase domain’s
affinity for ATP. Binding of ATP by the MSH6 subunit enhances the MSH2 subunit’s affinity
for ATP (Mazur et al., 2006, Heinen et al., 2011). When both subunits have bound ATP, the
MSH2-MSH6 heterodimer has been converted into a stable, DNA-bound clamp that diffuses
from the mismatch enabling it to be recognized by a new MSH2-MSH6 heterodimer and activate
another round of clamp-loading.
D. MMR molecular mechanism hypotheses
How MMR proteins involved in mismatch recognition link mismatch binding with the
excision of a mismatch-containing DNA strand remains unclear. There have been three models
proposed based on both prokaryotic and eukaryotic MMR biochemistry: static transactivation,
active translocation and molecular switch.
The static transactivation model proposes that MutS and MutL proteins complex directly
at a mismatch and use intervening loops in DNA to bring distant d(GATC) sites to the mismatch,
where MutS and MutL can activate MutH and incise the mismatch-containing DNA strand
(Junop et al., 2001; Schofield et al., 2001). Further biochemistry has largely eliminated the static
transactivation model of MMR. Additions of a protein “roadblock” and strand discontinuities,
which should not affect a model in which the MMR proteins remain bound at the mismatch,
severely inhibited activation of MutH and prevented excision (Pluciennik and Modrich, 2007;
Wang and Hays, 2004). The remaining two mechanistic models of MMR both rely on loading of
ATP-bound MutS or MSH2-MSH6 clamps followed by diffusion while maintaining residency
on the DNA. However the active translocation model posits that ATP binding then hydrolysis is
necessary for clamp movement from the mismatch (Allen et al., 1997) while the molecular
switch model posits that only ATP binding is necessary for clamp formation and diffusion from
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Figure 1-2. Schematic illustration of the steps in the yeast molecular switch model of
mismatch repair.

13

the mismatch (Figure 1-2; Gradia et al., 1999). Increasing biochemical evidence supports the
molecular switch model of MMR in vitro for both prokaryotes and eukaryotes (Jeong et al.,
2011; Cho et al., 2012), but little is known about the in vivo model of cellular MMR. The goal of
this research project was to validate the molecular switch model in cellular MMR as there is
currently a gap in knowledge regarding in vivo MMR.
E. MMR and the DNA damage response
Cells have evolved numerous, sometimes redundant, mechanisms to repair DNA damage
and prevent the transmission of genetic mutations to daughter cells. Often these mechanisms
involve detecting various DNA lesions during DNA replication and arresting the cell cycle while
the lesions are repaired or committing to apoptosis (Lazzaro et al., 2009). That genetic mutations
within the MMR pathway result in genomic instability can be understood given the biological
function of the system, but the survival advantage and cancer predisposition resulting therein is
somewhat paradoxical. If mutations are increasing in cells, it seems likely that those cells might
die more rapidly than a normal cell in which mutations are not increasing, but that is not the case
for cells that lack an intact MMR system. This is because the MMR pathway acts as a DNA
damage sensor, in addition to its role in mismatch repair, and localizes to chromatin in response
to alkylation damage to DNA (Adamson et al., 2005). The primary lesion that activates the
MMR-dependent DNA damage response (DDR) is O6-methylguanine (O6-me-G) lesions caused
by SN1 methylating agents like N-methyl-N’-nitro-N-nitrosoguanidine (MNNG; Christmann and
Kaina, 2000). The cellular mechanism of MNNG is similar to other commonly used alkylating
chemotherapeutics. There are two models to explain the role of the MMR system in O6-me-Ginduced cell cycle arrest and apoptosis: the futile repair cycle model and the direct signaling
model.
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a. Futile repair cycle
The name of this model is derived from the hypothesis that during DNA replication the
replicative polymerase will persistently mispair a thymine opposite an O6-me-G lesion in the
template DNA strand. Iterative rounds of unsuccessful MMR to remove the O6-me-G:T mispair
will result in persistent single-stranded (ss) DNA stretches and replication fork collapses during
another round of DNA replication (Kaina et al., 1997; Cejka et al., 2003). In vitro evidence for
this model came from a study that utilized a plasmid with a O6-me-G:T mismatch (York and
Modrich, 2006). The O6-me-G lesion could be repaired with eukaryotic, nick-directed MMR
when the nick was on the same strand as the O6-me-G lesion, but could not be repaired when the
nick was on the opposite strand (York and Modrich, 2006). In vivo evidence arose from the
observation that MNNG treatment caused persistent ssDNA gaps after the first cell cycle and cell
cycle arrest during the second round (Mojas et al., 2007; Stojic et al., 2004). Additionally,
persistent nuclear foci containing proteins associated with DNA repair and cell cycle arrest,
including the kinase ataxia telangiectasia and Rad3-related (ATR), indicated that these were sites
of DNA damage that were not being repaired (Stojic et al., 2004). Further work has supported
the futile repair cycle model as evidenced by a second round cell cycle arrest, but also indicated
that the concentration of MNNG used in experimentation may influence the cellular outcome. At
low doses, there is a shift towards using sister chromatid exchanges and homologous
recombination to overcome the O6-me-G lesion without a cell cycle arrest (Roos et al., 2009;
Quiros et al., 2010; Schroering and Williams, 2008). At high doses, cell death results from base
excision repair processing N3-me-A and N7-me-G lesions (Stojic et al., 2005).
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b. Direct signaling model
The second model to account for MMR-directed cell cycle arrest and apoptosis is the
direct signaling model. This model requires no iterative rounds of unsuccessful MMR; instead
cell cycle arrest effector proteins like ATR form complexes with MSH2-MSH6 and MLH1PMS2 at O6-me-G:T lesions that directly lead to activation of ATR-dependent Chk1 and cell
cycle arrest (Yoshioka et al., 2006). Additionally, treatment of MMR-proficient cancer cells with
cisplatin causes MSH2-MSH6-ATR binding and in MSH2-deficient cell lines this direct
interaction is not observed (Pabla et al., 2011). It is unclear if this direct interaction is occurring
at the cisplatin-induced DNA cross-links or nearby however.
F. Rationale
Development of MMR molecular mechanism models has largely been through the use of
in vitro biochemistry, small DNA oligonucleotides and recombinant proteins. Comparatively
little is known about human MMR in vivo where DNA exists as chromatin in association with
numerous proteins and in tightly-wound conformations. Indeed, biochemical evidence suggests
that nucleosomes reduce human MMR efficiency in vitro (Li et al., 2009). Development of
MMR models through biochemistry means it is unclear whether the field can make statements
about which MMR model is correct in human cells. The use of various MSH2 or MSH6 mutant
proteins is a tool that can allow us to make hypotheses about MMR models then selectively
inhibit the proposed mechanism at different points in order to generate data that might support a
proposed mechanism in human cells. Hargreaves et al. details the in vitro biochemical study of
eight Msh2 and Msh6 Saccharomyces cerevisiae mutants that all demonstrate differing levels of
nucleotide and mismatch binding and Msh2-Msh6 sliding clamp formation (Hargreaves et al.,
2010). The step-wise progression of Msh2-Msh6 binding mismatches, Msh2-Msh6 nucleotide
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exchange, sliding clamp formation and iterative sliding clamp loading that defines the molecular
switch model of MMR means that the Msh2 and Msh6 yeast mutants could be tools to validate
the molecular switch model of MMR in human cells. This would be the first evidence to support
a particular MMR model in human cells. We generated the human homologues of two Msh2
mutants from Hargreaves et al.: R711C and G827D. This study also utilized a previouslycharacterized MSH2 mutant, K675A, which contains a mutated conserved lysine residue in the
Walker box A ATP binding motif that directly coordinates with the ATP molecule. MSH2
K675A, R711C and G827D are all ATPase domain mutants. Using purified wild-type and
mutant MSH2-MSH6 proteins, we characterized the nucleotide binding, sliding clamp formation
and ATPase activity statuses of each heterodimer. To investigate MMR in vivo, we used a
lentivirus and an MSH2-null cancer cell line, Hec59. With the lentivirus, we restored expression
of MSH2 in Hec59 cells using the MSH2 ATPase domain mutants as well as wild-type MSH2
and lentivirus vector-only Hec59 as controls. We found that all MSH2 ATPase domain mutants
had decreased sliding clamp formation and ATPase activity relative to wild-type MSH2-MSH6.
In vivo, we found that MNNG treatment of Hec59 cells failed to induce an increase in MSH2
ATPase domain mutants’ chromatin localization despite being able to bind mismatches. MSH2
ATPase domain mutants were unable to repair a G/T mismatch-containing plasmid in vivo and
did not exhibit a MMR-dependent G2/M cell cycle arrest when mutant MSH2-expressing Hec59
cells were treated with MNNG. These data provide evidence that sliding clamp formation and
iterative sliding clamp loading on DNA is a necessary step for functional downstream MMR in
human cells. Support for sliding clamp formation and iterative sliding clamp loading in human
cells validates the molecular switch model of MMR in vivo.
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Chapter II:
Biochemical and cellular studies of MSH2 ATPase domain mutants support the molecular
switch model of mismatch repair in vivo.
A. ABSTRACT
The DNA MMR pathway is crucial in preventing genomic instability. Much of what is
known about the MMR pathway has been developed through in vitro biochemistry using bacteria
and yeast. It is unclear if the current mechanistic models of MMR extend to human cells in vivo
and if they have any functional relevance in the MMR-dependent DDR. We generated several
MSH2 ATPase domain mutants and characterized them using in vitro biochemistry in order to
investigate the molecular switch model of MMR in human cells. Using [γ-32P]-ATP, we
demonstrate that our MSH2 ATPase domain mutants do not bind ATP and this alters ATP
binding in the MSH6 subunit. As well, the MSH2 ATPase domain mutations inhibit ATP
hydrolysis by the MSH6 subunit. In vitro surface plasmon resonance (SPR) studies indicate that
the mutant MSH2-MSH6 heterodimers bind mismatches with increased Kd and do not form
sliding clamps efficiently. In an MSH2-null cell line, Hec59, we re-expressed the different
MSH2 ATPase domain mutants using a lentivirus. Using an in vivo MMR assay, all the MSH2
mutants were unable to direct MMR in vivo. Treatment of the lentiviral Hec59 cell lines with a
DNA alkylating agent failed to induce increased chromatin localization of the MSH2 ATPase
domain mutants or generate a MMR-dependent G2/M cell cycle arrest. All the MSH2 ATPase
domain mutants displayed significantly increased tolerance of DNA alkylation damage relative
to wild-type MSH2 as assessed using a clonogenic survival assay. This survival advantage was
eliminated using different DNA damaging agents. Taken together, the data suggest that the
molecular switch model of MMR is accurate for human cells in vivo and the cycle of nucleotide
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binding and sliding clamp formation is important for the MMR-dependent DDR to lesions
caused by alkylation damage, but not other DNA lesions.
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B. INTRODUCTION
The MMR pathway is a system for recognizing and repairing single nucleotide mispairs
that arise through DNA replication or following DNA damage. The MMR pathway is integral in
the maintenance of cell genomic stability. Mutations in the proteins that comprise the MMR
system cause LS, a hereditary cancer syndrome (Martín-López and Fishel, 2013). Broadly, DNA
mismatches are bound by a heterodimer of MSH2-MSH6, which forms a complex with a second
MMR protein heterodimer of MLH1-PMS2. This protein complex recruits and regulates the
activity of an exonuclease, EXO1, which removes the mismatch-containing strand. Resynthesis
of the degraded DNA strand and sealing is done by DNA polymerase δ and DNA ligase (Zhang
et al., 2005; Constantin et al., 2005; Dzantiev et al., 2004).
The exact molecular mechanism of coordinating mismatch binding with excision remains
unclear and multiple models have been developed. One model hypothesizes that MSH2 and
MSH6, the mismatch binding proteins, function as molecular switches activated by a mismatch
and ATP binding. Accordingly, it is called the molecular switch model of MMR (Gradia et al.,
1997). Multiple observations contributed to the development of this model. MSH2 and MSH6
both contain a highly-conserved ABC-ATPase domain capable of binding ADP and ATP and
hydrolyzing ATP (Hollenstein et al., 2007; Warren et al., 2007). Absent DNA binding, in vitro
biochemistry has demonstrated that MSH2 binds ADP while the MSH6 site is empty (Mazur et
al., 2006; Heinen et al., 2011). There is a conformational change in the MSH2-MSH6
heterodimer following mismatch binding that increases affinity in both MSH2 and MSH6
ATPase domain subunits for binding ATP (Gradia et al., 1999). Pre-binding ATP to MSH2MSH6 blocks mismatch binding (Gradia et al., 1997). Because of these observations, the
molecular switch model states that a DNA mismatch acts like a nucleotide exchange factor
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similar to those found in G-protein signaling (Fishel, 1998). Off of DNA, the MSH2 ATPase
subunit contains ADP while the MSH6 subunit is empty (Mazur et al., 2006; Heinen et al.,
2011). Upon binding to a mismatch, there is a conformational change that increases the affinity
of the MSH6 site for binding ATP. Once MSH6 has bound ATP, there is another small
conformational change that drives an ADP-ATP exchange at the MSH2 ATPase site. Off of
DNA MSH2-MSH6 are “off” and there is no MMR. Following mismatch and ATP binding,
MSH2-MSH6 are “on” and downstream MMR can proceed (Figure 1-2).
Other observations contributing to the formation of the molecular switch model of MMR
were the significantly increased MSH2-MSH6 residence time on DNA following ATP binding as
well as the loading of multiple MSH2-MSH6 heterodimers on the same mismatch-containing
DNA strand in vitro (Gradia et al., 1999). This observation led to the hypothesis that the MSH2MSH6 heterodimers were diffusing from the mismatch bidirectionally, but remaining on the
DNA. This allowed the mismatch to be recognized by a new MSH2-MSH6 heterodimer and
would lead to the iterative loading of hundreds to thousands of MSH2-MSH6 heterodimers.
These ultra-stable MSH2-MSH6 heterodimers are called sliding clamps in the molecular switch
model of MMR.
In addition to repairing single nucleotide mismatches, the MMR system is involved in a
DDR that can lead to cell cycle arrest and apoptosis. The MMR pathway recognizes numerous
DNA lesions, but the best-characterized and most cytotoxic are O6-me-G lesions caused by
alkylating agents like N-methyl-N’-nitro-N-nitrosoguanidine (MNNG; Christmann and Kaina,
2000). Cells with a functional MMR pathway are approximately 50-fold more sensitive to
MNNG than cells without functioning MMR (Karran, 2001). If cells replicate their DNA with
O6-me-G lesions, it can lead to O6-me-G:T mismatches that are recognized by the MMR
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pathway which causes a G2/M cell cycle arrest and can lead to apoptosis (Duckett et al., 1996;
Adamson et al., 2005).
Much of the mechanistic work on the MMR pathway has been developed through in vitro
biochemistry in bacteria and yeast. It is still unclear if the molecular switch model of MMR is
accurate in human cells or what this model’s contribution to the MMR-dependent DDR might
be, if any. Previous work identified yeast Msh2 and Msh6 ATPase domain mutants that were
deficient in mismatch repair (Hargreaves et al., 2010). One yeast Msh2 mutant, G855D, was
unable to bind ATP in the Msh2 subunit and had deficient sliding clamp formation, but was still
able to form complexes with Mlh1-Pms1. A second yeast Msh2 mutant, R730C, was able to bind
ATP in both the Msh2 and Msh6 subunits and bind Mlh1-Pms1, but was unable to form sliding
clamps. Given the fundamental importance of ATP binding and sliding clamp formation to the
molecular switch model of MMR, we hypothesized that generating the human homologs of the
yeast Msh2 ATPase domain mutants would selectively inhibit steps of the proposed mechanism
of the molecular switch model. By re-expressing the human MSH2 ATPase domain mutants,
G827D and R711C, and a previously described MSH2 Walker box A ATP binding motif mutant,
K675A (Heinen et al., 2011), in an MSH2-null Hec59 cell background we would be able to make
functional observations about the molecular switch model of MMR in human cells. These
observations could allow us to validate the molecular switch model of MMR in human cells for
the first time as well as investigate the requirement for the molecular switch model in the MMRdependent DDR.
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C. MATERIALS AND METHODS
Mismatch Repair Protein Preparation
R711C and G827D MSH2 ATPase domain mutations were generated using
QuikChange®-based PCR mutagenesis (Agilent Technologies). Wild-type, R711C and G827D
MSH2 heterodimers were expressed and purified as previously described (Heinen, 2002).
Generation and purification of the K675A MSH2 mutant is described elsewhere (Heinen, 2011).
Adenosine Nucleotide Binding
200 nM wild-type or MSH2 mutant-MSH6 protein was incubated with 250 nM [γ-32P]ATP for 20 minutes at room temperature in 25 mM Hepes (pH 8.1), 110 mM NaCl, 1 mM DTT,
5% glycerol, (+/-) 5 mM MgCl2 and (+/-) 1 mM EDTA. Samples were cross-linked for 10
minutes using a UV Stratalinker 1800 (Stratagene) and resolved using 6% SDS-PAGE. Gels
were dried and bands visualized using a Cyclon Storage Phosphor System (PerkinElmer). Bands
were quantified using ImageJ.
ATPase Assay
15-100 nM wild-type or MSH2 mutant-MSH6 protein was incubated with 16.5 nM [γ32

P]-ATP, 20-240 µM unlabeled ATP and a G/T mismatch-containing 41-bp oligonucleotide for

30 minutes at 37oC in 25 mM Hepes (pH 8.1), 100 mM NaCl, 10 mM MgCl2, 1 mM DTT and
15% glycerol (20 µl reaction volume). Reactions were quenched with 400 µl of 10% charcoal
and 1mM EDTA. Hydrolyzed [γ-32P]-ATP was detected using liquid scintillation following
charcoal pelleting.
Surface Plasmon Resonance Analysis
SPR analysis was carried out using the ProteOn™ XPR36 protein interaction array system
(Bio-Rad). A 60-base pair oligonucleotide with a central G/T mismatch and 5’ biotinylation was

23

bound to a neutravidin-containing NLC ProteOn™ sensor chip (Bio-Rad). Mismatch binding
strength analysis was carried out by injecting 0-120 nM protein over the chip at a rate of 30
µl/min for 3 min in a buffer containing 25 mM Hepes (pH 8.1), 110 mM NaCl, 1 mM DTT, 2
mM MgCl2 and 2% glycerol. Dissociation with buffer alone was observed for 3 min. Samples
were kept on ice prior to injection and experiments were carried out at 25oC. The sensor chip was
regenerated after each run by injecting 2.5 M NaCl at 100 µl/min for 1 min. Data were analyzed
using the ProteOn Manager™ software with a Langmuir fit. Non-specific binding was subtracted
using an interspot reference.
ATP-dependent dissociation off-rate analysis was completed by injecting 50 nM protein
over the chip for 3 min as above. ATP-dependent dissociation was observed by injecting an
identical buffer containing 50 nM ATP over the chip at 30 µl/min for 3 min. Data were exported
and analyzed using Prism 5 software (GraphPad) and a least-squares fit.
Generation of lentiviral cell lines
Wild-type and MSH2 mutant cDNAs were PCR-amplified and sub-cloned into the
lentiviral vector pCDH-EF1-MCS-T2A-Puro (System Biosciences). Lentivirus was generated
according to manufacturer’s protocol. Following transduction, Hec59 cells were maintained in
DMEM:F12 with 10% fetal bovine serum (Gibco) and 0.5 µg/mL puromycin (Gibco). Cells were
incubated at 37oC and 5% CO2.
Chemicals, reagents and antibodies
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) was obtained from the National Cancer
Institute Chemical Carcinogen Reference Standard Repository (CAS: 70-25-7). O6Benzylguanine (O6-BG) and hydroxyurea (HU) were from Sigma. Antibodies were: MSH2
(Western blot; BD Biosciences 556349; 1:1000), MSH2 (Immunoprecipitation; Calbiochem
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NA27), MSH6 (Bethyl A300-023A; 1:850), MLH1 (BD Biosciences 550838; 1:1000), TATAbinding protein (TBP; Abcam ab63766; 1:2000), Histone 3 (H3; Abcam ab24834; 1:2000) and
Actin (Sigma A5060; 1:5000).
Chromatin Localization Assay
Hec59 lentiviral cell lines were synchronized in S-phase with 2 mM HU for 18 h in
complete medium. At 16 h, cells were incubated with 25 µM O6-BG or an equivalent volume of
DMSO for 2 h. Cells were washed twice in phosphate-buffered saline (PBS) and treated with 25
µM O6-BG and 5 µM MNNG or an equivalent volume of DMSO for 4 h in complete medium
before harvesting. Cells were harvested with 0.25% trypsin (Gibco) then washed in PBS and 10
mM NaCl, 50 mM Tris-HCl (pH 7.5), 2 mM MgCl2. To remove cytosolic and nuclear soluble
proteins, cells were incubated on ice for 10 minutes in 10 mM NaCl, 50 mM Tris-HCl (pH 7.5),
2 mM MgCl2, 0.5 mM DTT, 0.5% NP-40 and protease and phosphatase inhibitors. Cells were
homogenized with a dounce homogenizer then nuclei were collected via centrifugation at 3400
rpm for 15 minutes. Nuclei were rotated at 4oC for approximately 45 minutes in 420 mM NaCl,
50 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 1 mM DTT, 5% glycerol, 0.75% Triton-X 100, 1 U
DNase I and protease and phosphatase inhibitors to create a protein fraction from chromatinassociated proteins. Protein extracts were separated by 10% SDS-PAGE and examined by
Western blot. Western blot images were developed using a ChemiDoc™ XRS+ imaging system
(Bio-Rad) and bands quantified with ImageJ. MSH2 band intensity was normalized to wild-type
MSH2 DMSO-treated. At least six separate experiments were quantified and the average fold
induction of MSH2 chromatin localization was determined using Prism 5 (GraphPad). Statistical
significance was determined with analysis of variance and Tukey’s post-test.
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In vivo MMR Assay
The heteroduplex repair plasmid (Zhou et al., 2009) was produced by transforming XL-1
blue cells with p111 plasmid. Infection with the M13KO7 phage (New England Biolabs)
produced viral particles that could be collected using polyethylene glycol precipitation. Singlestranded circular plasmid DNA was collected using CsCl centrifugation and phenol-chloroform
precipitated. Linearized p189 was denatured and annealed to the single-stranded p111 plasmid to
create a nick-directed heteroduplex repair plasmid. To assess in vivo MMR, cells were
transfected with 1.5 µg repair plasmid and 1.0 µg of an RFP-expressing plasmid as a transfection
efficiency control. Approximately 36 hours after transfection, GFP and RFP expression was
detected using a LSRII-B flow cytometer (BD Biosciences). GFP fluorescence was normalized
to RFP fluorescence to account for transfection efficiency differences. Analysis of variance was
performed to detect statistical differences between groups.
Cell Cycle Analysis
Hec59 lentiviral cell lines were synchronized with HU as above. At 16 h cells were
treated with 25 µM O6-BG for 2 h then with 1 µM MNNG plus 25 µM O6-BG for 48 h. At 48 h
cells were either released into normal growth medium to recover for 24 h (72 h time point) or
harvested and fixed in 70% ethanol at -20oC. Cells were stained in 20 µg/mL propidium iodide
and 200 µg/mL RNase A for 1 h at 37 oC. Cell cycle analyis was on a FACS Calibur flow
cytometer (BD Biosciences) using Modfit software (Verity Software House). All time points
were completed in duplicate.
Cell Survival Assays
Approximately 500 cells were plated and allowed to attach overnight. Cells were treated
with 25 µM O6-BG for 2 h then with the indicated [MNNG] and 25 µM O6-BG for 48 h. At 48 h,
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fresh growth medium was added and cells were allowed to recover for approximately 10 days.
To quantify, cells were harvested with 0.25% trypsin, washed with PBS, fixed in 100% methanol
and stained with crystal violet. 6-Thioguanine (6-TG; Meyers et al., 2005), 5-fluorouracil (5-FU;
Chen et al., 2010) and cisplatin (Aebi et al., 1996) survival assays were done as previously
described. Cells were harvested, fixed and stained as above. Student’s t-test was performed to
detect statistical differences between groups.

27

D. RESULTS
MSH2 ATPase domain mutants display differential nucleotide binding affinities in both
MSH2 and MSH6
The goal of this study was to validate the molecular switch model of MMR in vivo and
assess the contribution of ATP binding and sliding clamp formation to downstream MMR and
the MMR-dependent DDR in cells. To accomplish this, we generated MSH2 ATPase domain
mutations that were predicted to be deficient in one or more aspects of the molecular switch
model of human MMR based on previous biochemical work (Hargreaves et al., 2010; Heinen et
al., 2011; Figure 2-1).
Following recognition of a mismatch by the MSH2-MSH6 heterodimer, MSH6 and
MSH2 sequentially bind ATP and complete a conformational change that converts the MSH2MSH6 heterodimer into a MSH2-MSH6 sliding clamp that diffuses away from the mismatch
while remaining on the DNA according to the molecular switch model (Gradia et al., 1999).
Since sliding clamp formation is a fundamental step in the molecular switch model, we first
wanted to test the ability of the R711C and G827D mutants to bind ATP in both MSH2 and
MSH6 subunits. R711C and G827D mutants have a reduced ability to bind to ATP in MSH6 in
the absence of magnesium, which prevents hydrolysis of the gamma phosphate of ATP (Figure
2-2). The R711C mutant has an over 90% reduction in ATP binding by MSH2 and the G827D
mutant has no measurable ATP binding by MSH2 (Figure 2-2). However both mutants have
significantly increased binding by MSH6 in the presence of magnesium relative to the wild-type
control (Figure 2-2). The G827D mutation could occlude ATP from the MSH2 binding site while
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Figure 2-1. MSH2 ATPase domain mutations modeled in the MSH2-MSH6 heterodimer
crystal. A. Complete crystal structure of the MSH2-MSH6 heterodimer bound to ADP and G/T
mismatched DNA (protein data bank ID 2O8B) with the ATPase domains highlighted. B. Top
view of the ATPase domains of MSH2 and MSH6 with the locations of the MSH2 mutations
indicated in yellow, ADP in orange and magnesium in green.
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Figure 2-2. MSH2 ATPase domain mutations affect ATP binding. Representative
autoradiograph showing [γ-32P]-ATP binding by recombinant wild-type and MSH2 mutant
heterodimers with coomassie-stained total protein loading control below. 200 nM wild-type and
MSH2 mutant protein was incubated at room temperature with 250 nM [γ-32P]-ATP, crosslinked and separated using SDS-PAGE. Dried gels were exposed overnight and developed using
a phosphoimager. Quantification was carried out using ImageJ and is the result of three separate
experiments. Quantification is displayed with standard error of the mean.
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the R711C mutation is in a location that contributes to the integrity of the MSH2 ATP binding
site. The increased ATP binding seen in the presence of magnesium could indicate an inability of
these mutants to hydrolyze ATP. The K675A mutant is able to bind ATP at wild-type levels by
MSH6, but is completely unable to bind ATP by MSH2 (Heinen et al., 2011). This is not
surprising given that MSH2 lysine 675 is a highly conserved residue that is part of a Walker Box
A motif involved in ATP binding (Iaccarino et al., 1998). In the presence of magnesium, there is
no measurable detection of ATP binding by both MSH2 and MSH6 in the K675A mutant
(Heinen et al., 2011).
MSH2 ATPase domain mutants do not hydrolyze ATP
According to the molecular switch model of MMR, ATP-bound MSH2-MSH6 sliding
clamps must hydrolyze ATP following repair of a mismatch in order to return to a state that is
capable of recognizing mismatches once again (Gradia et al., 1997). W next asked if the mutants
could hydrolyze ATP. Both R711C and G827D had no ATPase activity above background as
measured by the release of the terminal ATP phosphate, γ-32P (Figure 2-3). The K675A mutant
had very modest ATPase activity (Heinen et al., 2011). This finding supports our hypothesis that
the increased ATP binding seen in the MSH6 subunit by the R711C and G827D mutants in the
presence of magnesium is due to a lack of ATPase activity (Figure 2-2). Taken together, the
R711C and G827D ATP binding and ATPase data indicate that both MSH2 and MSH6 make
important contributions to each other’s ATPase domains that are greater than the sum of the
parts. The K675A mutation is within a highly conserved ATP binding motif and only affects
ATP binding in the MSH2 subunit of the heterodimer, however the overall ATPase activity of
the MSH2-MSH6 heterodimer is significantly affected.
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Figure 2-3. MSH2 ATPase domain mutations affect ATP hydrolysis. 15-100 nM wild-type
and MSH2 mutant protein was incubated with a G/T mismatch-containing 41-base pair
oligonucleotide and [γ-32P]-ATP for 30 min. at 37oC. ATPase velocity was determined by
measuring the release of γ-32P using charcoal binding (Gradia et al., 1997). The curve was fitted
using a Michaelis-Menten equation. Error bars represent the standard error of the mean of at least
four separate experiments.
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MSH2 ATPase domain mutants bind G/T mismatches, but less efficiently than wild-type
Previous biochemical work (Mazur et al., 2006; Heinen et al., 2011) has supported the
molecular switch model of MMR in which the MSH2 subunit of the mismatch recognition
heterodimer binds ADP off of DNA while the ATP binding domain of MSH6 remains empty.
Binding to a mismatch increases ATP binding by MSH6, which drives an ADP-ATP exchange in
the MSH2 subunit. The dual ATP-bound form of MSH2-MSH6 is now free to diffuse from the
mismatch, but stably remain on the DNA. Since this is a fundamental step in the molecular
switch model of MMR, we first wanted to ask if R711C and G827D would bind to mismatches.
We used SPR and increasing concentrations of wild-type and MSH2 mutant MSH2-MSH6 to
measure the rate of association with a G/T mismatch (kon) and the strength of mismatch binding
(Kd). Both the R711C and G827D mutants were able to bind mismatches, but displayed slower
kon values relative to wild-type MSH2-MSH6 as well as increased Kd values (Table 2-1). The
increased Kd values of mismatch binding indicate that the MSH2 mutants may have structural
abnormalities that prevent mismatch binding as tightly as wild-type MSH2-MSH6.
MSH2 mutants undergo delayed ATP-dependent dissociation from mismatches
Since our MSH2 mutants were able to bind a G/T mismatch, but had significantly
reduced ATP binding by MSH2, we then asked whether there were any differences in their ATPdependent dissociation from mismatches. According to the sliding clamp model of MMR, ATPdependent dissociation of MSH2-MSH6 heterodimers results in the iterative loading of MSH2MSH6 heterodimers. Using SPR analysis as previously described (Cyr and Heinen, 2008), we
pre-bound wild-type and MSH2 mutant MSH2-MSH6 heterodimers to G/T mismatches then
dissociated using 50µM ATP (Figure 2-4). Experiments at 500µM and 250µM ATP showed no
difference in dissociation (data not shown) so we utilized a decreased [ATP] based on the
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Figure 2-4. MSH2 ATPase domain mutants bind G/T mismatches, but do not undergo
efficient ATP-dependent mismatch dissociation. SPR analysis of 50 nM wild-type or MSH2
mutant protein pre-bound to an oligonucleotide containing a central G/T mismatch and
dissociated with 50 nM ATP.
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hypothesis that the higher [ATP] were forcing MSH2 and MSH6 to bind ATP and form sliding
clamps. Both the R711C and G827D mutants showed slower ATP-dependent dissociation at
50µM indicating decreased sliding clamp formation. The K675A mutant did not form sliding
clamps as efficiently as wild-type MSH2-MSH6 in the presence of 250µM ATP (Heinen et al.,
2011). These data are consistent with the molecular switch model and indicate that the inability
of MSH2 ATPase domain mutants to properly bind ATP may result in these mutants remaining
associated with mismatches for longer periods of time. This would prevent the mismatches from
being recognized by additional MSH2-MSH6 heterodimers and accumulating multiple sliding
clamps on damaged DNA.
Restoring MSH2 expression in an MSH2-null cancer cell line, Hec59, leads to MSH6
protein stability
Following the biochemical characterization of the MSH2 ATPase domain mutants, we
used a lentivirus to transduce MSH2-null Hec59 endometrial cancer cells with wild-type,
ATPase domain mutant MSH2 or empty lentiviral vector under puromycin selection. The
presence of a T2A peptide, which adds water during protein translation (Donnelly et al., 2001),
in the puromycin resistance gene in the lentiviral vector ensures that anything cloned in-frame
into the multiple cloning site will be co-translated with puromycin resistance. Since Hec59 cells
are MSH2-null, using a lentivirus to restore MSH2 expression creates cell lines that stably
express wild-type or mutant MSH2 with which to study in vivo MMR. Restoring the expression
of any form of MSH2 in Hec59 cells stabilizes MSH6 (Figure 2-5). The G827D MSH2 Hec59
line appeared to have decreased MSH2 expression indicating that the G827D MSH2 protein may
not be as stable as the others. The lentiviral cell lines grew normally relative to non-transduced
Hec59 cells. MLH1 expression was unaffected by the re-expression of MSH2 (Figure 2-5).
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Figure 2-5. Expression of wild-type or mutant MSH2 stabilizes MSH6 protein in Hec59
cells. Wild-type or mutant MSH2 expression was restored in Hec59 cells using lentivirus
transduction. Approximately 50 µg of total protein was separated using 10% SDS-PAGE and
analyzed by Western blot with antibodies against MSH2, MSH6, MLH1. Actin was used as a
loading control.
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These data indicate it is possible to stably restore MSH2 expression in a human MSH2-null cell
background in order to ask questions about human cellular MMR.
MSH2 mutants do not localize to chromatin in response to DNA alkylation damage
With the new MSH2 Hec59 lentiviral cell lines, we first wanted to know if DNA
alkylation damage would induce the chromatin localization of our MSH2 mutants (Mastrocola
and Heinen, 2010a). Recruitment of MSH2-MSH6 heterodimers to mismatches and the
formation of multiple sliding clamps is necessary for downstream MMR and damage response
functions based on the molecular switch model of MMR. We synchronized the MSH2 Hec59
lentiviral cell lines with HU, treated them with 5µM MNNG for 4 hours then harvested the cells
and isolated soluble protein- and chromatin protein-enriched fractions. After treatment with
MNNG, the chromatin enriched levels of MSH2 increased almost 4-fold in the wild-type MSH2
Hec59 cells when compared to the mock (DMSO)-treated wild-type MSH2 cells (Figure 2-6).
None of the MSH2 mutants displayed an MSH2 chromatin localization induction in response to
alkylation damage (Figure 2-6). Combined with the SPR biochemical data that shows MSH2
mutants binding mismatches, but do not dissociate efficiently and form ATP-dependent sliding
clamps well, these data suggest that the MNNG-induced chromatin localization observed in
wild-type cells is due to sliding clamp formation, consistent with the molecular switch model.
MSH2 mutants can not repair mismatches in vivo
Since alkylation damage by MNNG did not induce increased chromatin localization of
the MSH2 mutants, the next question we wanted to ask was whether the MSH2 mutants were
able to repair mismatches in cells using a mismatch-containing GFP reporter plasmid (Zhou et
al., 2009). Repair of the mismatch results in GFP expression that can be detected by flow
cytometry. The lentiviral vector-only Hec59 cell line was unable to repair mismatches and
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Figure 2-6. MSH2 mutants do not localize to chromatin in response to MNNG treatment.
Representative Western blot image showing MSH2 chromatin recruitment in lentiviral Hec59
cell lines in response to MNNG. Lentiviral Hec59 cells were synchronized in S-phase using HU
and treated with O6-BG and 5 µM MNNG or DMSO for 4 hours. Chromatin-enriched extracts
were prepared 4 hours following HU release. Approximately 28 µg of total protein was separated
using 10% SDS-PAGE and analyzed by Western blot with antibodies against MSH2 and TBP as
a loading control. Quantification is the result of six separate experiments and represents the
average MSH2 fold change relative to DMSO-treated WT MSH2 Hec59 cell levels.
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Figure 2-7. MSH2 ATPase domain mutations eliminate in vivo MMR activity. A GFPencoding heteroduplex plasmid containing a premature stop codon was transfected into the
lentiviral Hec59 cell lines. A plasmid encoding RFP was co-transfected as a transfection
efficiency control. After 48 hours, fluorescence was detected using flow cytometry. Error bars
indicate the standard error of the mean of the averages of three separate experiments. Asterisks
indicate p < 0.001.
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restore GFP expression whereas re-expression of wild type MSH2 resulted in a significant
increase in GFP-positive cells (Figure 2-7). The G827D MSH2 Hec59 cell line was similarly
unable to repair mismatches in vivo. The R711C and K675A MSH2 Hec59 cell lines were unable
to significantly increase mismatch repair levels beyond the background vector-only level even
though they did display a slightly increased repair percent. Together, the MMR assay suggests
that all the MSH2 mutants are unable to repair mismatches in vivo.
MSH2 ATPase domain mutations increase alkylation resistance, but have no effect on
other DNA lesions
Cells deficient in MMR demonstrate increased resistance to alkylation damage-induced
cell cycle arrest and apoptosis (Adamson et al., 2005). To determine if the MSH2 mutants were
resistant to alkylation damage, we used a colony-forming assay with the MSH2 Hec59 cells
(Figure 2-8). Cells were plated out at low density and treated with low-doses of MNNG for 48
hours then allowed to recover for approximately 10 days. Following recovery, cells were fixed,
stained with crystal violet and colonies counted. At all doses of MNNG, the MSH2 mutant
Hec59 cells were significantly more resistant to the MNNG than wild-type MSH2 Hec59 cells
(Figure 2-8). However at 1µM MNNG, the R711C and K675A MSH2 Hec59 cell lines were
more sensitive to the alkylation damage than the G827D and LV vector-only Hec59 cell lines
(Figure 2-8). This indicates that the MMR-dependent DDR in the R711C and K675A MSH2
Hec59 cells could be partially intact though blunted. The MMR pathway is known to be involved
in detecting additional DNA lesions in addition to the cytotoxic O6-me-G caused by MNNG.
Because of this, we investigated the response of our Hec59 lentiviral cell lines to 6-TG, 5-FU
and cisplatin (Figure 2-9). A previously published report demonstrated a small difference
between Hec59 and Hec59 2-4 cells, in which MSH2 is re-expressed off chromosome 2, to 6-
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Figure 2-8. MSH2 ATPase domain mutations affect Hec59 cell survival in response to
alkylation damage. Lentiviral Hec59 cell lines were plated at low density and treated with O6BG and MNNG for 48 hours then allowed to recover for approximately 10 days in normal
growth media. Cells were washed, fixed, stained and counted to determine colony number. Error
bars indicate the standard error of the mean of the averages of three separate experiments done in
duplicate. Asterisk indicates p < 0.05.

50

51

Figure 2-9. MSH2 ATPase domain mutations do not affect Hec59 cell survival in response
to cisplatin, 6-TG and 5-FU. Lentiviral MSH2 mutant Hec59 cell lines were plated out at low
density and treated as previously described (Aebi et al., 1996; Chen et al., 2010;
Meyers et al., 2005).
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TG, but it was not clear if this difference was significant or not (Meyers et al., 2005). We did not
detect any significant differences between our Hec59 lentiviral cell lines. Another previously
published report did not find any significant difference between Hec59 and Hec59 2-4 cells in
response to 5-FU treatment (Chen et al., 2010). There was no difference between our Hec59
lentiviral cell lines in response to 5-FU treatment. It has previously been reported that there is an
approximately 2-fold increase in cisplatin tolerance in Hec59 cells relative to Hec59 2-4 cells
(Aebi et al., 1996). However, we detected no significant difference between our Hec59 lentiviral
cell lines when treated with various concentrations of cisplatin. All together, this indicates that
MMR is primarily involved in the detection of alkylation damage and the O6-me-G lesion caused
by MNNG in particular and plays a smaller role in the detection and potential repair of these
other lesions.
MSH2 ATPase domain mutations prevent MMR-dependent G2/M cell cycle arrest
Because of the decreased survival at 1µM MNNG by the R711C and K675A MSH2
Hec59 cells, we wanted to investigate whether this decreased colony-forming response was due
to apoptosis or an activated cell cycle checkpoint. Cells with intact MMR, which are treated with
an alkylating agent, cell cycle arrest in the second G2/M and undergo apoptosis (Mastrocola and
Heinen, 2010b). We treated the MSH2 Hec59 lentiviral cell lines with 1µM MNNG for 48 hours
then harvested or allowed 24 hours recovery in normal growth media before harvesting and
staining with propidium iodide for flow cytometry analysis. All mock-treated and untreated cells
cycled normally. After 48 hours in 1µM MNNG, wild-type MSH2 Hec59 cells displayed a
strong G2/M arrest characteristic of cells with an intact MMR response while lentiviral vectoronly Hec59 cells showed no G2/M arrest (Figure 2-10). None of the MSH2 mutant Hec59 cell
lines showed any G2/M arrest in response to MNNG alkylation damage. After 24 hours recovery,
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wild-type MSH2 Hec59 cells remain arrested in G2/M, but now have a substantial sub-G1 peak
indicating apoptosis. Even after 24 hours recovery, none of the MSH2 mutant Hec59 cells arrest
in G2/M or undergo apoptosis. These data suggest that the DDR is impaired by the mutations in
the MSH2 ATPase domain.

54

55

Figure 2-10. MSH2 ATPase domain mutations prevent MMR-dependent G2/M cell cycle
arrest in Hec59 cells. Representative flow cytometry plots showing cell cycle progression in
lentiviral Hec59 cell lines after MNNG treatment. Lentiviral Hec59 cell lines were treated with
O6-BG and 1 µM MNNG for 48 hours then harvested or allowed to recover for 24 hours. Cells
were washed, fixed, stained with propidium iodide then analyzed for DNA content using flow
cytometry.

56

E. DISCUSSION
The MMR pathway is an important system to preserve genomic integrity as evidenced by
the hereditary cancer syndrome, LS, which is caused by inherited mutations in the MMR
pathway. Most of the work done on the MMR pathway has been in vitro biochemistry in yeast
and bacteria. There is far less data about MMR in humans. The eukaryotic biochemical data has
suggested three possible mechanisms whereby mismatch recognition, strand discrimination and
excision are linked: static transactivation, active translocation and molecular switch. The static
transactivation model posits that MSH2-MSH6 remain bound at a mismatch and bend the DNA
until a distant initiation site for strand excision is encountered (Junop et al., 2001; Schofield et
al., 2001). This model has fallen into disfavor since the observation that protein “roadblocks”
prevent strand excision, an outcome not predicted by the model (Pluciennik and Modrich, 2007;
Wang and Hays, 2004). The active translocation model hypothesizes that MSH2-MSH6 bind
ATP while bound to a mismatch, but hydrolysis of the ATP provides energy for movement along
the DNA helix until a site for initiation of strand excision is found (Allen et al., 1997). The third
model, molecular switch, is similar to the active translocation model except movement from the
mismatch is ATP hydrolysis-independent and only requires ATP binding (Gradia et al., 1997). In
this manner, the mismatch is continually available to be bound by MSH2-MSH6 heterodimers
until excision removes it. Thus numerous MSH2-MSH6 sliding clamps accumulate along the
DNA bidirectionally (Gradia et al., 1999).
Since these models were all developed through in vitro biochemistry it is unclear which one, if
any, reflect human cellular MMR. The biochemistry used to generate mechanistic MMR models
utilizes small linear and circular heteroduplexes of naked DNA, which is unlike the chromatin
MMR would be repairing in cellular nuclei. Indeed, there is biochemical evidence that
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nucleosomes inhibit MMR efficiency in vitro (Li et al., 2009). The goal of this study was to
validate the molecular switch model of MMR in human cells using MSH2 ATPase domain
mutants, unable to complete key steps predicted by the molecular switch model like ATP binding
and sliding clamp formation, then re-expressed in an MSH2-null background, Hec59, to create
stable cell lines to work with and study in vivo human MMR.
Previously published work detailed numerous yeast Msh2 ATPase domain mutants that
were deficient in nucleotide binding, sliding clamp formation and Mlh1-Pms1 binding
(Hargreaves et al., 2010). The mismatch-provoked ADP to ATP exchange by MSH2-MSH6
heterodimers and subsequent sliding clamp formation are key steps in the molecular switch
model of MMR. In order to investigate the molecular switch model in vivo, we had to
biochemically characterize MSH2 homologues of the yeast Msh2 mutants. Both MSH2 and
MSH6 have composite ATPase sites with each protein subunit contributing to the other’s
ATPase site. The MSH6 ATPase domain is more disordered and flexible than the MSH2 ATPase
domain (Warren et al., 2007). The two MSH2 mutants we generated based on the work of
Hargreaves et al., R711C and G827D, plus the MSH2 Walker A motif mutant, K675A, are all
deficient at binding ATP in the MSH2 subunit, but all three retain some ATP binding capacity in
the MSH6 subunit with the MSH2 K675A mutant having wild-type MSH2-MSH6 levels (Heinen
et al., 2011). The inability of the R711C and G827D mutants to bind ATP in the MSH2 site
could be explained by these mutations disrupting the more structured MSH2 ATPase domain
thereby making it more disordered like the MSH6 site. Although the R711C and G827D MSH2
mutations are not near the MSH6 ATPase site (Figure 2-1), the greatly reduced ATP binding
observed in the MSH6 subunit for these mutations suggests that these regions are structurally
involved both in the conformational change that accompanies mismatch binding and the general
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structure of the composite MSH6 ATPase site. The K675A MSH2 mutation is highly-conserved
in directly coordinating with the ATP molecule that it is not surprising that this mutation has no
effect on ATP binding by the MSH6 subunit. It is not involved structurally in the composite
ATPase domain sites of MSH2 and MSH6. SPR studies indicated that all three MSH2 ATPase
domain mutants were able to bind mismatches albeit G827D doing so much less efficiently than
the K675A and R711C mutants. All three MSH2 mutants formed ATP-dependent sliding clamps
less efficiently than wild-type MSH2-MSH6 with the G827D MSH2 mutant being the least
efficient. None of the MSH2 mutants had any significant ATPase activity. Our results suggest
that the MSH2 ATPase domain mutants can not dissociate readily from mismatches because of
the ATP binding deficiencies that prevent them from finalizing the conformational change
necessary to form sliding clamps. This observation and the lack of ATPase activity indicates that
the MSH2 ATPase domain mutants may act as dominant negatives in the cell both by preventing
other MSH2-MSH6 heterodimers from recognizing mismatches and being unable to hydrolyze
bound ATP, a necessary step towards recycling sliding clamps into a MSH2-MSH6 heterodimer
that is capable of binding mismatches once more.
Since our goal was to validate the molecular switch model of MMR in vivo and we had
MSH2 mutants that were deficient at key steps of the model, we re-expressed these MSH2
mutants in an MSH2-null cell line, Hec59, to prevent any interference from wild-type MSH2.
Using these MSH2 mutants we were able to stabilize MSH6. Using an established in vivo MMR
assay (Zhou et al., 2005) we observed that the MSH2 mutants were unable to direct MMR in
cells. This is consistent with our hypothesis that ATP binding and sliding clamp formation are
key steps to in vivo human MMR. Treating MMR-proficient cells with MNNG induces
chromatin localization of MSH2-MSH6 followed by MLH1-PMS2 (Mastrocola and Heinen,
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2010b). We observed no increase in MSH2 mutant chromatin localization following MNNG
treatment of the Hec59 cell lines, but a significant increase in wild-type MSH2 chromatin
localization. Given the ability of the MSH2 mutants to bind mismatches, especially the K675A
and R711C mutants, it seems likely that the nearly four-fold increase in wild-type MSH2 on
chromatin in response to MNNG we observed is due to repetitive loading of MSH2-MSH6
sliding clamps at single mismatches.
Cells that lack an intact MMR system have an almost 50-fold higher tolerance for
alkylation damage caused by MNNG than do cells with intact MMR (Karran, 2001). It is still
unclear if key steps in the molecular switch model, namely sliding clamp formation, are
necessary to mediate the MMR-dependent DDR. There are two models to account for MMR
involvement in detecting and communicating DNA damage, the futile repair cycle model and
direct signaling model. The futile repair cycle model posits that MMR does not actually remove
the O6-me-G, but instead removes the mismatched thymine opposite it, which will lead to
repetitive and unsuccessful repair attempts. This led to the hypothesis that replication fork
collapses, double-strand breaks and stretches of ssDNA during the second cell cycle were
responsible for a DNA damage-induced cell cycle arrest (Kaina et al., 1997; Mojas et al., 2007;
Stojic et al., 2004). This model is supported by the observation of persistent ssDNA gaps and a
MMR-dependent G2/M arrest in the second cell cycle. The direct signaling model posits that
MSH2-MSH6 and MLH1-PMS2 directly signal to ATR and ATR-interacting protein (ATRIP)
while bound to a mismatch (Yoshioka et al., 2006; Adamson et al., 2005; Liu et al., 2010). This
model is supported by a co-immunoprecipitation study that found direct interactions between a
complex of MMR proteins and ATR-ATRIP when O6-me-G:T lesions were present (Yoshioka et
al., 2006). The differences between the two models, namely one requires actual MMR and the
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other merely requires the presence of MMR proteins at mismatches, allows us to use our MSH2
mutants to observe whether the mutant MSH2 Hec59 lines would activate a MMR-dependent
G2/M arrest. We observed that all three MSH2 mutants failed to activate a G2/M cell cycle arrest
in response to alkylation damage induced by MNNG. As well, all three MSH2 mutants displayed
significantly increased alkylation tolerance relative to wild-type MSH2 Hec59 cells using a
clonogenic survival assay. The inability of the MSH2 mutants to carry out in vivo MMR, localize
to chromatin in response to MNNG and lack of G2/M arrest seems to support the futile repair
cycle model and demonstrate a requirement for the molecular switch model of MMR in vivo.
However it is unclear if the MSH2 mutants can bind to MLH1-PMS2 in vivo so the direct
signaling model can not be dismissed. Taken together, the data suggest that ATP binding by both
MSH2 and MSH6 and sliding clamp formation and accumulation on DNA are essential steps for
both in vivo human MMR and the MMR-dependent DDR. This suggests that the molecular
switch model of MMR is correct in human cells in vivo.

61

Chapter III: Conclusions and Future Directions
The aim of this project was to validate the molecular switch model of MMR in human
cells and investigate a contribution for this model towards the MMR-dependent DDR. We
generated MSH2 ATPase domain mutants predicted to be deficient at key steps of the molecular
switch model and validated them using in vitro biochemistry. We re-expressed these MSH2
mutants in MSH2-null Hec59 cells and treated them with MNNG in order to study the role of the
molecular switch model of MMR in vivo and its role in the MMR-dependent DDR.
A. MSH2 ATPase domain mutations impair MSH2-MSH6 sliding clamp formation
MSH2 ATPase domain mutants were unable to bind ATP in the MSH2 subunit. MSH6
ATP binding was unaffected for K675A, but significantly reduced for R711C and G827D. ATP
hydrolysis was deficient for all MSH2 mutants and efficient sliding clamp formation was
impaired relative to wild-type MSH2-MSH6 sliding clamps.
Previous work from our lab observed a negative correlation between mismatch binding
and ATPase activity in MSH2 mutants (Heinen et al., 2002), however also uncovering some
MSH6 mutations that uncoupled ATPase activity from mismatch binding (Cyr and Heinen,
2008). The R711C MSH2 mutant appears to uncouple mismatch binding from the MSH2-MSH6
heterodimer’s ATPase activity while the G827D mutant has reduced mismatch-binding
capabilities, although it is still able, as well as a complete lack of ATPase activity. Both the
R711C and G827D MSH2 mutants have difficulty with ATP-dependent dissociation from
mismatches. Binding to a mismatch by MSH2-MSH6 is known to be asymmetric with MSH6
being the actual mismatch-binding subunit. While both MSH2 and MSH6 have composite
ATPase domains comprised of amino acid contributions from the other half, the MSH6 site is
less structured than the MSH2 site (Warren et al., 2007). The data here suggest that some regions
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of the more-structured MSH2 ATPase domain can occlude the MSH6 ATP binding site. Given
the nature of the MSH2 ATPase mutations it is possible that this occlusion is either based on
steric hindrance, in the case of the G827D mutation, or due to a charge attraction/repulsion. This
would inhibit the mismatch binding-provoked ATP binding by the MSH6 ATPase domain. In
turn, this would disrupt the conformational change that the MSH6 ATPase domain is predicted to
communicate to the MSH2 ATPase domain that increases its affinity for ATP and allows MSH2MSH6 sliding clamp formation. Previous work has demonstrated that mutations of the lysine in
the Walker A ATP binding motif of MSH2, which eliminates ATP binding, does not affect the
ATPase activity of the MSH2-MSH6 heterodimer as strongly as mutating the Walker A lysine in
the MSH6 ATPase domain (Iaccarino et al., 1998). Additionally, MSH6 has a stronger affinity
for ATP than does MSH2 (Mazur et al., 2006; Heinen et al., 2011). The data here support the
previous findings that ATP binding by both MSH2 and MSH6 are crucial for overall ATPase
activity by the MSH2-MSH6 heterodimer. Based on our observations of the MSH2 mutants, the
ATPase activity of the MSH2-MSH6 heterodimer does not appear necessary for some ATPdependent dissociation from mismatches. Overall, the data support a model where our MSH2
ATPase domain mutants bind and remain at mismatches longer than wild-type MSH2-MSH6
heterodimers and do not undergo efficient ATP-dependent mismatch dissociation. The study of
single amino acid substitutions in MSH2 and MSH6 can be valuable in MMR research whether
they are obtained naturally from LS patients or generated through hypothesis-driven research.
The predicted MSH6 ATPase domain occlusion and MSH2 ATPase domain conformational
change inhibition by the R711C and G827D MSH2 mutants could be tested with crystallography
or NMR to illuminate the details of how the two MSH2 and MSH6 composite ATPase sites
communicate with one another. Trypsin proteolysis could be used prior to determine if there is
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an actual difference in conformational change or not. Additional amino acid substitutions in socalled “intersite” areas (Hargreaves et al., 2010) between the two ATPase domains, such as
MSH2 R711C, provide the best opportunity to study the composite nature of the two ATPase
domains. The Walker A motif that coordinates nucleotide binding in the MSH2 and MSH6
ATPase domains is complemented by the Walker B ATPase motif that coordinates ATP
hydrolysis. The Walker B hydrolyzes ATP using a highly-conserved hhhhDE where ‘h’ is any
hydrophobic amino acid and the glutamate is the essential amino acid residue for ATP hydrolysis
(Hanson and Whiteheart, 2005). As there is still a mechanistic model of MMR that requires ATP
hydrolysis to initiate downstream MMR, the active translocation model, an investigation into a
Walker B mutant with the essential catalytic glutamate mutated could eliminate the active
translocation model provided ATP binding by both MSH2 and MSH6 was unaffected and the
ATPase activity of the MSH2-MSH6 heterodimer was eliminated. SPR experiments with longer,
mismatch-containing oligonucleotides and a blocked-end could determine if the MSH2 mutant
proteins are dissociating from mismatches and remaining on DNA or simply falling off when
challenged with ATP. Knowing this could clarify results obtained from in vivo experiments.
B. MSH2 ATPase domain mutants are alkylation damage tolerant and can not repair
mismatches
All MSH2 ATPase domain mutants were unable to repair mismatches in vivo. Treating
our lentiviral MSH2 Hec59 cell lines with MNNG failed to induce increased chromatin
localization to O6-me-G:T mismatches and did not cause a MMR-dependent G2/M cell cycle
arrest. Using a clonogenic survival assay, the MSH2 mutant Hec59 cell lines were significantly
more alkylation tolerant than wild-type MSH2 when treated with MNNG, but not in response to
6-TG, 5-FU or cisplatin.
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Based on the results of the MSH2 ATPase domain mutant in vitro biochemistry, we
hypothesized that the K675A MSH2 mutant could be capable of in vivo MMR, but the R711C
and G827D mutants would not be. All three MSH2 mutants were incapable of coordinating nickdirected human MMR in vivo. This supports previous findings from our lab that MSH2 ATPase
domain mutants tend to have more severe phenotypes than mutations found elsewhere
(Mastrocola and Heinen., 2010a). Our hypotheses based on the molecular switch model of MMR
were that ATP binding by both MSH2 and MSH6 and sliding clamp formation were crucial steps
for in vivo MMR. The in vivo MMR data support our hypothesis that the molecular switch model
of MMR is accurate in human cells. In response to MNNG treatment and generation of O6-meG:T mismatches, the Hec59 cells with mutant MSH2 failed to undergo an increase in chromatin
localization as predicted by our previous work (Mastrocola and Heinen, 2010b) and also failed to
activate a MMR-dependent G2/M cell cycle arrest. Since the MSH2 mutants do bind mismatches,
this indicates that the lack of chromatin localization observed is not from an inability to bind
mismatches. It appears to be an inability to repetitively load MSH2-MSH6 heterodimers at
mismatches, which supports the molecular switch model of MMR. We observed no MMRdependent G2/M cell cycle arrest following MNNG treatment in any of the MSH2 mutants. This
could indicate that repetitive formation of MSH2-MSH6 sliding clamps is a necessary step in the
activation of MMR-dependent cell cycle arrest, which would place the molecular switch model
of MMR upstream of any MMR-dependent DDR. Additionally, this observation could indicate
that in vivo repair is required to activate the MMR-dependent DDR, which would support the
futile repair cycle model. An important future direction for this work is to determine if the
ATPase domain mutant MSH2-MSH6 heterodimers can interact with the second MMR
heterodimer, MLH1-PMS2. Binding ATRIP and ATR at O6-me-G:T mismatches in a complex
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with MLH1-PMS2 is a key feature of the direct signaling model (Yoshioka et al., 2006) and both
MSH2-MSH6 and MLH1-PMS2 form complexes with ATR and additional DNA damage
signaling proteins after MNNG-induced alkylation damage (Liu et al., 2010). If the MSH2
mutants can interact with MLH1-PMS2, it could be strong evidence to support the futile repair
cycle model of MMR-dependent DDR. We observed that the Hec59 cells re-expressing ATPase
domain mutant MSH2 were significantly more alkylation tolerant than Hec59 cells re-expressing
wild-type MSH2 using a clonogenic survival assay, however the K675A and R711C MSH2
Hec59 cells were slightly more sensitive than the lentiviral vector and G827D Hec59 cells. Our
work has demonstrated that the MSH2 mutant Hec59 cells can not repair mismatches in vivo and
do not undergo a typical MMR-dependent G2/M arrest or apoptosis. A possible explanation is
that the K675A and R711C MSH2 mutant Hec59 cells have restored expression of MGMT, an
enzyme that non-reversibly catalyzes the removal of the methyl group from the O6 of guanine
(Kaina et al., 2007), which is inhibited during our assays. This might slow down cell growth
giving the appearance of slightly increased sensitivity to MNNG when none actually exists.
Given the subjectivity of the clonogenic survival assay, repeating a few more times may clarify
whether there is a true separation for the K675A and R711C mutants or whether it is an
experimental artifact. Previous reports have all documented differences between MMR-deficient
Hec59 cells and MMR-proficient Hec59 2-4, which have had human chromosome 2 containing
MSH2 restored, following treatment with 6-TG (Meyers et al., 2005) , 5-FU (Chen et al., 2010)
and cisplatin (Aebi et al., 1996). The failure of our clonogenic survival assay to detect any
differences between the various MSH2-expressing Hec59 cells could be due to the subjective
nature of the assay as well as the slight differences in tolerance between the MMR-proficient
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Hec59 2-4 and MMR-deficient Hec59 cells relative to the much more pronounced tolerance of
alkylation damage demonstrated by MMR-deficient Hec59 cells.
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